Phase 1/2 For a New PARP1 Inhibitor: EIK1004 (IMP1707) For mCRPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1/2 Trial: MT-4561 Targeting BRD4 in Metastatic Prostate Cancer and Neuroendocrine Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxNEPC
Real-World Studies Suggest Survival Advantage with Apalutamide in mCSPC Treatment
/in Retrospective studies/by MaxPhase 2 Trial: ZG006 a New Immunotherapy for Neuroendocrine Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 3 Trial: Ifinatamab Deruxtecan (MK-2400) for metastatic Castration-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 1 Trial: HSK46575 a Novel CYP11A1 Inhibitor for mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1/2 Trial: Targeting Resistance With SX-682 And Apalutamide or Enzalutamide
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1 Trial for DR-0202 Bispecific Antibody for Solid Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 48/2025 November 30, 2025
- Phase 1/2 Trial for MK-6070: A Promising Trispecific T-Cell Engager for Neuroendocrine Cancers November 29, 2025
- UPDATE: Phase 1 GenSci143 Trial Set To Start By The End of December November 27, 2025
- Phase 2 Trial for The Combo Fasudil Hydrochloride Plus PD-1 Immune Checkpoint Blockade November 27, 2025